Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study analyzing duration of B-cell depletion in patients treated with ocrelizumab or rituximab for Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorders

Next Previous
Trial Profile

A retrospective study analyzing duration of B-cell depletion in patients treated with ocrelizumab or rituximab for Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorders

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary) ; Rituximab (Primary)
  • Indications Multiple sclerosis; Neuromyelitis optica
  • Focus Therapeutic Use

Most Recent Events

  • 26 Apr 2022 Results assessing the duration of B-cell depletion in a cohort of patients receiving ocrelizumab or rituximab for MS or NMOSD presented at the 74th Annual Meeting of the American Academy of Neurology 2022
  • 07 Apr 2022 New trial record
  • 26 Feb 2022 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top